×
验证码:
换一张
Forgotten Password?
Stay signed in
Login With UMPASS
English
|
繁體
Login With UMPASS
Log In
ALL
ORCID
TI
AU
PY
SU
KW
TY
JN
DA
IN
PB
FP
ST
SM
Study Hall
Image search
Paste the image URL
Home
Faculties & Institutes
Scholars
Publications
Subjects
Statistics
News
Search in the results
Faculties & Institutes
Faculty of Healt... [2]
Institute of Chi... [1]
Authors
ZHAO QI [2]
ZHANG QINGWEN [1]
Document Type
Journal article [4]
Date Issued
2024 [1]
2022 [2]
2017 [1]
Language
英語English [2]
Source Publication
Chemical Enginee... [1]
JOURNAL OF MEDIC... [1]
Journal of Leuko... [1]
Journal of leuko... [1]
Indexed By
SCIE [4]
IC [1]
Funding Organization
Funding Project
×
Knowledge Map
UM
Start a Submission
Submissions
Unclaimed
Claimed
Attach Fulltext
Bookmarks
Browse/Search Results:
1-4 of 4
Help
Selected(
0
)
Clear
Items/Page:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Sort:
Select
Issue Date Ascending
Issue Date Descending
Journal Impact Factor Ascending
Journal Impact Factor Descending
WOS Cited Times Ascending
WOS Cited Times Descending
Submit date Ascending
Submit date Descending
Title Ascending
Title Descending
Author Ascending
Author Descending
NIR-II excitation self-assembly nanomedicine for targeted NIR-IIa fluorescence imaging-guided cuproptosis-promoted synergistic therapy against triple-negative breast cancer
Journal article
Dai Yeneng, Leng Dongliang, Guo Ziang, Wang Jiaqi, Gu Yuheng, Peng Yingjun, Zhu Lipeng, Zhao Qi. NIR-II excitation self-assembly nanomedicine for targeted NIR-IIa fluorescence imaging-guided cuproptosis-promoted synergistic therapy against triple-negative breast cancer[J]. Chemical Engineering Journal, 2024, 479, 147704.
Authors:
Dai Yeneng
;
Leng Dongliang
;
Guo Ziang
;
Wang Jiaqi
;
Gu Yuheng
; et al.
Adobe PDF
|
Favorite
|
TC[WOS]:
21
TC[Scopus]:
4
IF:
13.3
/
13.2
|
Submit date:2024/01/25
Nir-ii Excitation
Self-assembly
Amplified Cuproptosis
Nir-iia Fluorescence Imaging
Targeted Therapy
2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy
Journal article
Peng, Yingjun, Fu, Shengyu, Zhao, Qi. 2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy[J]. Journal of leukocyte biology, 2022, 112(4), 823-834.
Authors:
Peng, Yingjun
;
Fu, Shengyu
;
Zhao, Qi
Favorite
|
TC[WOS]:
7
TC[Scopus]:
7
|
Submit date:2023/08/28
2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy
Journal article
Yingjun Peng, Shengyu Fu. 2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy[J]. Journal of Leukocyte Biology, 2022, 112(4), 823-834.
Authors:
Yingjun Peng
;
Shengyu Fu
Favorite
|
TC[WOS]:
7
TC[Scopus]:
7
IF:
3.6
/
5.2
|
Submit date:2022/08/05
Cytokine
Il-15
Il-2
Immunotherapy
Protein Engineering
Structure Based Design of N-(3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzenesulfonamides as Selective Leucine-Zipper and Sterile-alpha Motif Kinase (ZAK) Inhibitors
Journal article
Chang, Yu, Lu, Xiaoyun, Shibu, Marthandam Asokan, Dai, Yi-Bo, Luo, Jinfeng, Zhang, Yan, Li, Yingjun, Zhao, Peng, Zhang, Zhang, Xu, Yong, Tu, Zheng-Chao, Zhang, Qing-Wen, Yun, Cai-Hong, Huang, Chih-Yang, Ding, Ke. Structure Based Design of N-(3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzenesulfonamides as Selective Leucine-Zipper and Sterile-alpha Motif Kinase (ZAK) Inhibitors[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60(13), 5927-5932.
Authors:
Chang, Yu
;
Lu, Xiaoyun
;
Shibu, Marthandam Asokan
;
Dai, Yi-Bo
;
Luo, Jinfeng
; et al.
Favorite
|
TC[WOS]:
21
TC[Scopus]:
20
IF:
6.8
/
7.1
|
Submit date:2018/10/30